Myriad Genetics Inc. announced Tuesday it has been awarded a U.S. patent for a method of determining an individual's predisposition to hypertension (high blood pressure) based upon the angiotensinogen gene (AGT). This is Myriad's fourth patent on the AGT gene, which forms the basis of the company's CardiaRisk (TM) test.

The additional patent reinforces Myriad's proprietary position in AGT while reaffirming the its leadership in molecular diagnostics. Myriad was also awarded a patent on the p16 (MTS1) tumor suppressor gene.